Perrigo Company PLC

Perrigo Company PLC(PRGO)の株式分析

$16.630

+0.151 (+0.91%)終値時点

Loading chart…
高値
16.680
始値
16.540
出来高加重平均価格
16.52
出来高
2.44M
時価総額
—
安値
16.260
売買代金
40.31M
EV/EBITDA(TTM)
9.24

Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief.

www.perrigo.com

AI分析 of Perrigo Company PLC (PRGO)

買い

Perrigo Company PLC is a good buy right now due to its current price of $15.06 being below the analyst target price of $15.25, suggesting room for growth. Additionally, the stock has shown a 5-day change of +5.61%, indicating positive momentum. However, investors should be cautious of the company's recent financial challenges, including a net income loss of $398.6 million in Q1 2026, which poses a risk to profitability.

アナリスト評価(18)

上値余地 +22.25%
中立
6 買い
11 中立
1 売り
現在: 16.63
安値
18.00
平均
20.33
高値
23.00

JPMorgan

2026-02-27

目標株価

$15

中立

Canaccord

2026-02-27

目標株価

$17

買い

JPMorgan

2025-12-15

目標株価

$18

中立

Canaccord

2025-11-06

目標株価

$20

買い

JPMorgan

2025-11-06

目標株価

$20

中立

バリュエーション指標

Perrigo Company PLC(PRGO)の現在の予想PERは5.97で、5年平均は10.60です。

予想PER

割安
5年平均 P/E
10.60
現在のP/E
5.97
割高
14.57
割安
6.63

予想EV/EBITDA

適正
5年平均 EV/EBITDA
9.36
現在のEV/EBITDA
9.24
割高
13.30
割安
5.43

予想PSR

割安
5年平均 P/S
0.84
現在のP/S
0.56
割高
1.10
割安
0.59

Alphio AI による PRGO の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%PRGO

$33.09

シナリオ価格

基

基本

基本 · 50%PRGO

$30.61

シナリオ価格

弱

弱気

弱気 · 25%PRGO

$29.15

シナリオ価格

PRGO を保有するクジラ

B

BW Gestao de Investimentos Ltda.

+ を保有PRGO

+2.45%

3か月リターン

S

Sound Income Strategies, LLC

+ を保有PRGO

-3.77%

3か月リターン

イベントタイムライン

2026-10-09 (ET)

16:30:00

Rumor of Perrigo Takeover Highlighted in Blog

2026-08-05 (ET)

07:00:00

Company Reports Q2 Revenue of $1.02B, Exceeding Expectations

07:00:00

Company Lowers FY26 Revenue Outlook by 1.5%-5.5%

2026-06-30 (ET)

17:00:00

Perrigo Appoints Salman Amin and Omer Gajial as Independent Directors

2026-06-10 (ET)

13:40:00

Perrigo rumor highlighted in Betaville blog

ニュース

PRGO のよくある質問 — Alphio AI が回答

Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Perrigo Company PLC is a good buy right now due to its current price of $15.06 being below the analyst target price of $15.25, suggesting room for growth. Additionally, the stock has shown a 5-day change of +5.61%, indicating positive momentum. However, investors should be cautious of the company's recent financial challenges, including a net income loss of $398.6 million in Q1 2026, which poses a risk to profitability.

18 analysts cover PRGO: 6 rate it Buy, 11 Hold and 1 Sell. The average price target is 20.33.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める